A new medication has been approved for patients with HIV infection who, after receiving multiple treatments, have exhausted other options because of drug resistance, intolerance, or safety issues.
Fostemsavir, marketed as Rukobia, is a first-in-class HIV-1 attachment inhibitor that converts in the body to temsavir, which blocks the glycoprotein 120 subunit on the virus’ surface from attaching to and infecting CD4+ T cells. Because it’s the first medication that targets this step in the viral cycle, manufacturer Viiv Healthcare said in a statement that cross-resistance with other antiviral drugs isn’t an issue.
Voelker R. First-in-Class HIV Drug Is Approved. JAMA. 2020;324(5):433. doi:10.1001/jama.2020.13103
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: